Caris Life Sciences (NASDAQ:CAI) Coverage Initiated at Robert W. Baird

Research analysts at Robert W. Baird assumed coverage on shares of Caris Life Sciences (NASDAQ:CAI) in a note issued to investors on Tuesday, MarketBeat reports. The brokerage set an “outperform” rating and a $26.00 price target on the stock. Robert W. Baird’s target price would indicate a potential upside of 23.52% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Evercore set a $38.00 target price on shares of Caris Life Sciences in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Canaccord Genuity Group boosted their price target on shares of Caris Life Sciences from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $31.33.

Caris Life Sciences Stock Performance

Caris Life Sciences stock opened at $21.05 on Tuesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 9.36 and a current ratio of 9.93. Caris Life Sciences has a one year low of $20.27 and a one year high of $42.50. The stock has a market capitalization of $5.94 billion and a PE ratio of -45.76. The company has a 50-day simple moving average of $25.55.

Insider Buying and Selling at Caris Life Sciences

In other news, insider Luke Thomas Power sold 62,250 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $26.58, for a total value of $1,654,605.00. Following the completion of the transaction, the insider owned 99,571 shares in the company, valued at $2,646,597.18. This trade represents a 38.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Management LLC raised its holdings in Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after acquiring an additional 755 shares in the last quarter. Global Retirement Partners LLC lifted its position in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after purchasing an additional 999 shares during the last quarter. Olistico Wealth LLC acquired a new position in shares of Caris Life Sciences during the fourth quarter worth approximately $31,000. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Caris Life Sciences by 15.0% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 11,932 shares of the company’s stock valued at $322,000 after purchasing an additional 1,560 shares during the period. Finally, PEAK6 LLC boosted its holdings in shares of Caris Life Sciences by 6.9% in the fourth quarter. PEAK6 LLC now owns 24,800 shares of the company’s stock valued at $669,000 after acquiring an additional 1,600 shares in the last quarter.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.